The impact of free fatty acid (FFA-) suppression on myocardial lipids and function in patients with type 2 diabetes

The impact of free fatty acid (FFA-) suppression on myocardial lipids and function in patients with type 2 diabetes - HYPOTESIS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-002656-32-AT

Enrollment

Registered

2013-07-02

Start date

2013-07-23

Completion date

Unknown

Last updated

2016-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Trade Name: Olbetam Product Name: Olbetam Kapseln Product Code: 1-19221 Pharmaceutical Form: Capsule INN or Proposed INN: acipimox CAS Number: 51037300 Current Sponsor code: NA Other descriptive name:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis of type 2 diabetes HbA1C between =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Insulin therapy, except basal insulin adjusted to oral agents known heart disease incl. coronary artery disease, cardiomyopathy and history of cardiac surgery known intolerance against niacins known contraindications against magnetic resonance examinations

Design outcomes

Primary

Measure	Time frame
Main Objective: Changes in myocardial lipids and function related to suppression of free fatty acids;Secondary Objective: Changes in hepatic lipid content related to suppression of free fatty acids;Primary end point(s): Change in myocardial lipids/ejection fraction after FFA-suppression;Timepoint(s) of evaluation of this end point: after 180 and 240 minutes as well as 24 hours after administration of acipimox	—

Measure

Time frame

Main Objective: Changes in myocardial lipids and function related to suppression of free fatty acids;Secondary Objective: Changes in hepatic lipid content related to suppression of free fatty acids;Primary end point(s): Change in myocardial lipids/ejection fraction after FFA-suppression;Timepoint(s) of evaluation of this end point: after 180 and 240 minutes as well as 24 hours after administration of acipimox

—

Secondary

Measure	Time frame
Timepoint(s) of evaluation of this end point: after 180 and 240 minutes as well as 24 hours after administration of acipimox;Secondary end point(s): changes in hepatic lipid content	—

Countries

Austria

Contacts

Public ContactYvonne Winhofer

Medizinische Universität Wien, Univ.Klinik für Innere Medizin III, Abt.f.Endokrinologie und Stoffwechsel

yvonne.winhofer@meduniwien.ac.at00431404004311

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026